BIOSYENT INC (RX.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:RX - CA0906901081 - Common Stock
RX.CA Key Statistics, Chart & Performance
The current stock price of RX.CA is 11.82 CAD. In the past month the price increased by 11.62%. In the past year, price increased by 1%.
RX.CA Latest News, Press Relases and Analysis
RX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.78 | 3.50B | ||
| CRON.CA | CRONOS GROUP INC | 25.87 | 1.49B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.32B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.47 | 926.40M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.39 | 668.48M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 598.72M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 585.85M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 431.06M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 15.92 | 367.61M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 351.94M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 307.62M | ||
| HITI.CA | HIGH TIDE INC | N/A | 301.88M |
Related stock screener links
About RX.CA
Company Profile
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Company Info
BIOSYENT INC
2476 Argentia Road, Suite 402
Mississauga ONTARIO L5N 6M1 CA
CEO: Rene Goehrum
Employees: 0
Phone: 18884390013
BIOSYENT INC / RX.CA FAQ
What does RX do?
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
What is the stock price of BIOSYENT INC today?
The current stock price of RX.CA is 11.82 CAD. The price decreased by -3.43% in the last trading session.
Does RX stock pay dividends?
BIOSYENT INC (RX.CA) has a dividend yield of 1.67%. The yearly dividend amount is currently 0.18.
How is the ChartMill rating for BIOSYENT INC?
RX.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
How is the valuation of BIOSYENT INC (RX.CA) based on its PE ratio?
The PE ratio for BIOSYENT INC (RX.CA) is 19.06. This is based on the reported non-GAAP earnings per share of 0.62 and the current share price of 11.82 CAD.
Can you provide the upcoming earnings date for BIOSYENT INC?
BIOSYENT INC (RX.CA) will report earnings on 2026-03-11.
RX.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RX.CA. When comparing the yearly performance of all stocks, RX.CA is a bad performer in the overall market: 64.05% of all stocks are doing better.
RX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA. RX.CA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
RX.CA Financial Highlights
Over the last trailing twelve months RX.CA reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 24.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.47% | ||
| ROA | 18.07% | ||
| ROE | 21.64% | ||
| Debt/Equity | 0.02 |
RX.CA Forecast & Estimates
7 analysts have analysed RX.CA and the average price target is 13.77 CAD. This implies a price increase of 16.5% is expected in the next year compared to the current price of 11.82.
For the next year, analysts expect an EPS growth of 20.96% and a revenue growth 23.16% for RX.CA